Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $50.24 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 04/23/15 All times are local (Market data is delayed by at least 15 minutes).

ipsen (IPSEF) Snapshot

Open
$50.24
Previous Close
$50.24
Day High
$50.24
Day Low
$50.24
52 Week High
04/23/15 - $50.24
52 Week Low
08/14/14 - $43.25
Market Cap
4.2B
Average Volume 10 Days
15.0
EPS TTM
--
Shares Outstanding
83.1M
EX-Date
05/29/15
P/E TM
--
Dividend
$0.85
Dividend Yield
2.16%
Current Stock Chart for IPSEN (IPSEF)

Related News

No related news articles were found.

ipsen (IPSEF) Related Businessweek News

View More BusinessWeek News

ipsen (IPSEF) Details

Ipsen S.A. operates as a pharmaceutical company worldwide. It offers drugs in the areas of uro-oncology, endocrinology, neurology, gastroenterology, cardiovascular, and cognitive disorders. The company’s products include Decapeptyl, a peptide formulation for injection in the treatment of advanced prostate cancer; Hexvix that is used to enhance detection of bladder cancer; and Somatuline and Somatuline Autogel, which are used in the treatment of acromegaly and neuroendocrine tumours. Ipsen S.A. also offers NutropinAq, a liquid formulation used in the treatment of growth failure in children and growth hormone deficiency in adults; Increlex, a formulation used for the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor 1 deficiency; and Dysport, a botulinum neurotoxin type A complex used to treat spasticity of upper limbs following a stroke, as well as the spasticity of other muscles. In addition, it provides Smecta, a natural clay-based drug used in the treatment of chronic and acute diarrhea; Forlax, a drug based on a linear polyethylene glycol polymer used in the treatment of constipation; and Tanakan that is used in the treatment of age-related cognitive disorders. Further, the company offers Nisis and Nisisco oral formulations containing valsartan used in the treatment of hypertension; and Adenuric for the treatment of gout. Additionally, it is developing products in the areas of neurology, endocrinology, and uro-oncology, including BN82451, Tasquinimod, Somatuline Autogel, Dysport, Dysport Next Generation, and Decapeptyl. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A.

4,304 Employees
Last Reported Date: 03/30/15
Founded in 1929

ipsen (IPSEF) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: €1.8M
Deputy Chief Executive Officer and Interim Ex...
Total Annual Compensation: €1.4M
Compensation as of Fiscal Year 2014.

ipsen (IPSEF) Key Developments

Ipsen S.A. Reports Sales Results for the First Quarter of 2015; Provides Sales Guidance for the Full Year of 2015

Ipsen S.A. reported sales results for the first quarter of 2015. The firm has reported financial results for the first quarter of the year posting a sales growth of 14.4% year on year on a reported basis to EUR 350.1 million (USD 382.2 million), or 11.7% year on year increase in constant exchange rates (CER). The sales growth continued to be driven by specialty car products which grew 18% year on year or 14.6% year on year in CER. Ipsen posted a strong start to the year, with group sales increasing 11.7% year on year at CER or 14.4% year on year on a reported basis in the first quarter of the year.

Ipsen and Hannover Medical School Joint Research Collaboration Agreement to Develop New Therapeutics for Patients

Ipsen and Hannover Medical School announced that they have entered into a joint research collaboration agreement. The objective is to develop new therapeutics for patients with serious neurological, endocrinological or oncological disease. The research program aims at testing recombinant botulinum neurotoxin proteins to affect intracellular molecular pathways with targeted secretion inhibitors (TSIs). Ipsen's proprietary platform of TSI proteins is selectively able to deliver neurotoxin endopeptidase into defined target cells and inhibit pathological secretion from that cell. This technology is based upon the endopeptidase activity found within clostridial (botulinum) neurotoxins, which cleaves SNARE proteins that have a fundamental role in vesicular cell secretion.

Ipsen Signs Multi-Year Research Alliance Agreement with Harvard University

Ipsen announced that it has signed a multi-year research alliance agreement with Harvard University. Designed to stimulate new research projects, the alliance will enable researchers at Ipsen and Harvard to identify and develop collaborative programs in the areas of neuroendocrine tumors, neuromuscular disorders, and platform technologies related to toxins and peptides. The agreement builds upon the success of an existing, three-year program initiated in July 2013: supported by Ipsen, the Harvard laboratory of Dr. Min Dong is engineering novel recombinant botulinum toxin molecules that may improve upon the therapeutic characteristics of existing treatments for neuromuscular tremors and spasms.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPSEF:US $50.24 USD 0.00

IPSEF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Daiichi Sankyo Co Ltd ¥2,095 JPY +9.50
H Lundbeck A/S kr129.40 DKK +0.80
View Industry Companies
 

Industry Analysis

IPSEF

Industry Average

Valuation IPSEF Industry Range
Price/Earnings 25.3x
Price/Sales 2.9x
Price/Book 3.7x
Price/Cash Flow 25.7x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IPSEN, please visit www.ipsen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.